REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Hua Medicine (Shanghai) (China)

Main Activities: Research and Development in Biotechnology (except Nanobiotechnology)
Full name: Hua Medicine Profile Updated: July 06, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

Hua Medicine is a drug developer that focuses on developing a oral drugs - Dorzagliatin or HMS5552 - for the treatment of Type 2 diabetes. The company was founded in 2009 and is headquartered in Shanghai, China.

Headquarters
275 Ai Di Sheng Road
Shanghai; Shanghai; Postal Code: 201203

Contact Details: Purchase the Hua Medicine (Shanghai) report to view the information.

Website: http://www.huamedicine.com

Basic Information
Total Employees:
Purchase the Hua Medicine (Shanghai) report to view the information.
Outstanding Shares:
Purchase the Hua Medicine (Shanghai) report to view the information.
Registered Capital:
Purchase the Hua Medicine (Shanghai) report to view the information.
Financial Auditors:
Purchase the Hua Medicine (Shanghai) report to view the information.
Incorporation Date:
2009
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Chief Executive Officer
Purchase this report to view the information.
Chief Financial Officer
Purchase this report to view the information.
Director/Member of the Board
Purchase this report to view the information.
Director/Member of the Board
Ownership Details
Purchase this report to view the information.
11.86%
Purchase this report to view the information.
9.81%
Purchase this report to view the information.
7.02%
Purchase this report to view the information.
2.39%
Purchase this report to view the information.
Subsidiaries
Hua Medicine Technology (Hong Kong) Limited (Hong Kong SAR, China)
100%
Hua Medicine Usa Inc (United States)
100%
Company Performance
Financial values in the chart are available after Hua Medicine (Shanghai) report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency CNY. Absolute financial data is included in the purchased report.
Net sales revenue
45.97%▲
Total operating revenue
50.82%▲
Operating profit (EBIT)
-53%▼
EBITDA
-48.86%▼
Net Profit (Loss) for the Period
-57.88%▼
Total assets
44.92%▲
Total equity
N/A
Operating Profit Margin (ROS)
-6.47%▼
Net Profit Margin
-10.45%▼
Return on Equity (ROE)
N/A
Debt to Equity Ratio
N/A
Quick Ratio
0.91%▲
Cash Ratio
0.87%▲

Similar companies

Pharmaron Beijing Co., Ltd. (康龙化成(北京)新药技术股份有限公司)
 
Shanghai Haohai Biological Technology Co.,Ltd
Shandong Boan Biotechnology Company Limited (Heze) (山东博安生物技术股份有限公司 (菏泽))
 
Boji Medical Technology Co.,Ltd.
Jiangsu Bioperfectus Technologies Co., Ltd.
 
Ascentage Pharma Group International (Hong Kong) (亚盛医药集团-B (香港))
JW Cayman Therapeutics Company Limited
 
Brii Biosciences Limited
Abbisko Cayman Limited
 

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo